Missak Haigentz is an Oncology physician affiliated with Rutgers. OpenAlex indexes 222 publications with 6,773 citations (h-index 45); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
195 Little Albany St
New Brunswick, NJ 089011914
Telephone
732-235-2465Provider last certified this registry record 4 Nov 2021.
Clinical trials
- ATATcH Alternating Treatment Plans for Advanced Cancer
Sponsor: Rutgers, The State University of New Jersey
- Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
Sponsor: National Cancer Institute (NCI)
- Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
29.4%Kinase inhibitor26.8%Tagrisso52%Lenvima27%Mekinist10%Tafinlar10%Part D<11 patientsOther antineoplastic agents2.5%Krazati100%Part D<11 patientsHormonal (systemic)
21.2%l-Thyroxine21.2%Levothyroxine Sodium100%Part D≥24 patientsMetabolism & gastrointestinal
18.9%Dopamine-2 Receptor Antagonist6.7%Metoclopramide Hcl100%Part D≥24 patientsSerotonin-3 Receptor Antagonist5%Ondansetron Odt100%Part D≥24 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Clinical Trial Support for the Rutgers Cancer Institute and the RWJBarnabas Health System
Rutgers Biomedical and Health Sciences
FY2026$975,000UG1CA308666 - The Atlantic Health Cancer Consortium Community Oncology Research Program (AHCC CORP)
Atlantic Health System, Inc.
FY2019$1,079,764UG1CA239772
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Sherine Gabriel, MD
Rutgers
Julius Gardin, MD
Rutgers
Abraham Aviv, MD
Rutgers
Partho Sengupta, MD, DM
Rutgers
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”